Tucson, AZ, July 23, 2021 --(PR.com)-- NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics with the issuance of US Patent No. 10946097, “Fractionated radiotherapy and chemotherapy with an oxygen therapeutic,” describing a new method of treating cancer utilizing Company’s lead drug candidate, NanO2TM, and its administration to reverse tumor hypoxia.
Search
Recent Posts
See AllTucson, AZ, May 9th, 2022 – https://www.pr.com/press-release/861001 NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases whe
Tucson, AZ, April 19, 2022 -- https://www.pr.com/press-release/859633 NuvOx Pharma’s technology, which is developed as a first-in-class therapeutic to treat life-threatening diseases where hypoxia pla
Tucson, AZ, April 17, 2022 -- https://www.pr.com/press-release/859467 NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases wh